Wang Yuan-Yuan, Lin Si-Xiang, Yang Gui-Qing, Liu Han-Chen, Sun Dong-Ning, Wang Yi-Shan
School of Integration of Traditional and Western Medicine, Binzhou Medical University;
School of Integration of Traditional and Western Medicine, Binzhou Medical University; ; Center for Tumor Treatment, The People's Liberation Army 107th Hospital, Yantai, Shandong 264002, P.R. China.
Mol Clin Oncol. 2013 May;1(3):527-530. doi: 10.3892/mco.2013.95. Epub 2013 Mar 19.
Non-small cell lung cancer (NSCLC) is responsible for at least 80% of all lung tumors and has a poor prognosis, since 75% of NSCLCs are first diagnosed at an advanced stage. This study was conducted to evaluate the therapeutic efficacy of CyberKnife in combination with chemotherapy and hyperthermia for selected patients with advanced non-small cell lung cancer (NSCLC). Clinical charts, imaging and pathology reports of patients with advanced NSCLC who underwent CyberKnife therapy in our Tumor Therapy Center were retrospectively reviewed. Clinical efficacy was evaluated for local control, Karnofsky performance status scale (KPS) and toxicity analysis. A total of 119 patients with 136 target areas were evaluated. A prescribed dose of 24-51 Gy to the gross tumor volume was delivered in 3-6 fractions. The median prescription dose was 35 Gy (mean, 34.73±4.80 Gy), with an average of five fractions. Patients, who voluntarily participated in the study, were assigned to one of three groups, which were as follows: CyberKnife therapy alone, CyberKnife combined with chemotherapy and CyberKnife combined with chemotherapy and hyperthermia. The median follow-up period was 6 months and curative efficiencies were 62.16, 71.79 and 90.70%, respectively, as determined by radiographic and clinical re-examinations. Patients treated by CyberKnife combined with chemotherapy and hyperthermia achieved optimal improvement in the aspect of KPS, which was statistically different compared to the other two groups (P<0.05). In conclusion, our results indicated that CyberKnife combined with chemotherapy and hyperthermia achieved favorable short-term outcomes and may be a more viable option for patients with advanced NSCLC. However, further investigations are required to evaluate long-term outcomes.
非小细胞肺癌（NSCLC）占所有肺部肿瘤的至少80%，且预后较差，因为75%的非小细胞肺癌首次诊断时已处于晚期。本研究旨在评估射波刀联合化疗和热疗对部分晚期非小细胞肺癌（NSCLC）患者的治疗效果。对在我们肿瘤治疗中心接受射波刀治疗的晚期NSCLC患者的临床病历、影像学和病理报告进行了回顾性分析。对局部控制、卡氏功能状态量表（KPS）和毒性分析进行了临床疗效评估。共评估了119例患者的136个靶区。对大体肿瘤体积给予24 - 51 Gy的处方剂量，分3 - 6次给予。中位处方剂量为35 Gy（平均，34.73±4.80 Gy），平均5次。自愿参与研究的患者被分为三组，如下：单纯射波刀治疗组、射波刀联合化疗组和射波刀联合化疗及热疗组。中位随访期为6个月，经影像学和临床复查确定的治愈率分别为62.16%、71.79%和90.70%。射波刀联合化疗及热疗治疗的患者在KPS方面取得了最佳改善，与其他两组相比有统计学差异（P<0.05）。总之，我们的结果表明，射波刀联合化疗和热疗取得了良好的短期疗效，可能是晚期NSCLC患者更可行的选择。然而，需要进一步研究来评估长期疗效。
